AU2022254741A1 - Treatment of cancer with kdm4 inhibitors - Google Patents
Treatment of cancer with kdm4 inhibitors Download PDFInfo
- Publication number
- AU2022254741A1 AU2022254741A1 AU2022254741A AU2022254741A AU2022254741A1 AU 2022254741 A1 AU2022254741 A1 AU 2022254741A1 AU 2022254741 A AU2022254741 A AU 2022254741A AU 2022254741 A AU2022254741 A AU 2022254741A AU 2022254741 A1 AU2022254741 A1 AU 2022254741A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- fold
- diagnosed
- patient
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163173219P | 2021-04-09 | 2021-04-09 | |
| US63/173,219 | 2021-04-09 | ||
| US202163252542P | 2021-10-05 | 2021-10-05 | |
| US63/252,542 | 2021-10-05 | ||
| US202263297960P | 2022-01-10 | 2022-01-10 | |
| US63/297,960 | 2022-01-10 | ||
| PCT/US2022/024087 WO2022217100A1 (en) | 2021-04-09 | 2022-04-08 | Treatment of cancer with kdm4 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022254741A1 true AU2022254741A1 (en) | 2023-11-16 |
Family
ID=83545127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022254741A Pending AU2022254741A1 (en) | 2021-04-09 | 2022-04-08 | Treatment of cancer with kdm4 inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250025451A1 (https=) |
| EP (1) | EP4319748A4 (https=) |
| JP (1) | JP2024518712A (https=) |
| AU (1) | AU2022254741A1 (https=) |
| CA (1) | CA3214399A1 (https=) |
| WO (1) | WO2022217100A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3600301B1 (en) | 2017-03-30 | 2024-07-03 | Albert-Ludwigs-Universität Freiburg | Kdm4 inhibitors |
| KR20250067936A (ko) * | 2022-09-21 | 2025-05-15 | 셀진 코포레이션 | 3-({[(4r)-7-{메틸[4-(프로판-2-일)페닐]아미노}-3,4-디하이드로-2h-1-벤조피란-4-일]메틸}아미노)피리딘-4-카르복실산l-라이신 염의 결정형, 히스톤 탈메틸화효소 억제제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0307643D0 (en) * | 2003-04-02 | 2003-05-07 | Cyclacel Ltd | Markers |
| UY35395A (es) * | 2013-03-12 | 2014-10-31 | Abbvie Inc | Inhibidores de bromodominios tetracíclicos |
| SI3160952T1 (sl) * | 2014-06-25 | 2021-07-30 | Celgene Quanticel Research, Inc. | Zaviralci histon demetilaz |
| EP3600301B1 (en) * | 2017-03-30 | 2024-07-03 | Albert-Ludwigs-Universität Freiburg | Kdm4 inhibitors |
| WO2019083594A1 (en) * | 2017-08-21 | 2019-05-02 | The General Hospital Corporation | COMPOSITIONS AND METHODS FOR CLASSIFYING TUMORS WITH INSTABILITY OF MICROSATELLITES |
| UY38349A (es) * | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| WO2023023112A1 (en) * | 2021-08-18 | 2023-02-23 | Celgene Corporation | Process for preparing histone demethylase inhibitors |
-
2022
- 2022-04-08 JP JP2023562492A patent/JP2024518712A/ja active Pending
- 2022-04-08 WO PCT/US2022/024087 patent/WO2022217100A1/en not_active Ceased
- 2022-04-08 EP EP22785559.0A patent/EP4319748A4/en active Pending
- 2022-04-08 US US18/554,283 patent/US20250025451A1/en active Pending
- 2022-04-08 AU AU2022254741A patent/AU2022254741A1/en active Pending
- 2022-04-08 CA CA3214399A patent/CA3214399A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4319748A1 (en) | 2024-02-14 |
| WO2022217100A1 (en) | 2022-10-13 |
| EP4319748A4 (en) | 2025-02-26 |
| JP2024518712A (ja) | 2024-05-02 |
| US20250025451A1 (en) | 2025-01-23 |
| CA3214399A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Manni et al. | JMJD family proteins in cancer and inflammation | |
| JP7323592B2 (ja) | 癌を治療するための併用療法 | |
| US20220062240A1 (en) | Methods of treating cancer using a clk inhibitor | |
| Campagna et al. | Nicotinamide N‐methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines | |
| JP7462789B2 (ja) | Idh1阻害剤耐性対象の治療方法 | |
| US20250025451A1 (en) | Treatment of cancer with kdm4 inhibitors | |
| AU2020417223A1 (en) | Treatment of cancer with CDK12/13 inhibitors | |
| WO2012178038A1 (en) | Methods of treating cancer | |
| Soucie et al. | Molecular basis of mast cell disease | |
| JP7163495B2 (ja) | B細胞リンパ腫の治療のための医薬組成物 | |
| CN116209452A (zh) | 用于治疗aml的疗法和rara激动剂、低甲基化剂和bcl-2抑制剂的用途 | |
| US8598188B2 (en) | Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer | |
| US20210079384A1 (en) | Non-invasive detection of response to a targeted therapy | |
| WO2015134603A2 (en) | Methods for treating cancer | |
| JPWO2019039390A1 (ja) | 若年性骨髄単球性白血病治療薬 | |
| CN114574580A (zh) | 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用 | |
| US20210260057A1 (en) | Compositions and methods targeting glutamine and its metabolism for diagnosing and treating cancer and therapy-associated side effects | |
| JP2022513375A (ja) | NAMPTi感受性のバイオマーカーとしてのPPM1D変異の同定法 | |
| Liu et al. | RHCG inhibition promotes the sensitivity of PIK3CA-mutant non-small lung cancer to PI3K inhibitor [J] | |
| CN116904588B (zh) | Linc01633在胃癌诊断和治疗中的应用 | |
| JPWO2011078312A1 (ja) | 肝細胞癌患者に対する化学療法の治療効果予測方法 | |
| US20220184029A1 (en) | Compositions and methods for treating neuroblastoma | |
| CA3036568C (en) | Methods for treating ovarian cancer | |
| Zhou et al. | PDK1 elevation was induced by epigenetic modifications of KDM3A and METTL16 to mediate TKI resistance and cancer development | |
| Zhang et al. | RETRACTED: L1-ATP8B1 Exacerbates High-Level Reduction-Oxidation Homeostasis to Promote Carcinogenesis via Affecting PHB1 Sumoylation in LUSC |